HFRG
ARCT icon

Houlihan Financial Resource Group’s Arcturus Therapeutics ARCT Stock Holding History

Houlihan Financial Resource Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21,700
Closed -$591K – 98
2023
Q2 		$591K Buy
+21,700
New +$591K 0.02% 104
2020
Q3 		$17K Buy
+350
New +$17.4K 0.01% 242

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Houlihan Financial Resource Group's ARCT Position: Q3 2023 in Review

Houlihan Financial Resource Group sold out of Arcturus Therapeutics (ARCT) in Q3 2023, closing a stake of 21,700 shares — an estimated $591K sold.

Houlihan Financial Resource Group first reported a position in ARCT in Q3 2020 and held it in 2 quarters. The position peaked at $591K in Q2 2023. 145 funds tracked by Wall St. Rank hold ARCT as of Q3 2023.

  • Houlihan Financial Resource Group reported no remaining Arcturus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Houlihan Financial Resource Group sold 21,700 Arcturus Therapeutics shares in Q3 2023, an estimated $591K.
  • Houlihan Financial Resource Group first reported a position in Arcturus Therapeutics in Q3 2020 and held it in 2 quarters.
  • Houlihan Financial Resource Group's Arcturus Therapeutics position peaked at $591K in Q2 2023.
  • 145 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2023.

Based on Houlihan Financial Resource Group's 13F filing for Q3 2023, filed 9 Nov 2023.